Table 1: In vitro/in vivo efficacy of the HIV drugs selected for COVID-19.
| Drug | In vitro activity | In vivo activity (animal models) | Clinical studies |
| SARS-CoV-1 MERS-CoV | SARS-CoV-1 MERS-CoV | ||
| Lopinavir/ritonavir (Kaletra); Used in HIV infection | +/- - [8] [9] |
Not studied +/- [9] |
Weak efficacy for
SARS-CoV-1 [8] Negative results for MERS-CoV [9] |
| Abacavir/Lamivudine/Zidovudine
(Trizivir) Used in HIV infection |
Not studied | Not studied | Ongoing for
COVID-19 [Actual work] |